Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 4:02 pm Sale |
2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC |
Palo Alto Investors LP | 1,611,787 1.540% |
-3,625,497 (-69.22%) |
Filing History |
| 2024-02-14 4:55 pm Sale |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Palo Alto Investors LP | 5,237,284 5.960% |
-46,325 (-0.88%) |
Filing History |
| 2024-02-14 4:54 pm Purchase |
2023-12-31 | 13G | eHealth, Inc. EHTH |
Palo Alto Investors LP | 2,739,379 9.660% |
254,900 (+10.26%) |
Filing History |
| 2024-02-14 4:52 pm Sale |
2023-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
Palo Alto Investors LP | 340,146 4.450% |
-36,899 (-9.79%) |
Filing History |
| 2023-04-03 2:24 pm Sale |
2023-03-24 | 13G | Alimera Sciences, Inc. ALIM |
Palo Alto Investors LP | 0 0.000% |
-802,423 (Position Closed) |
Filing History |
| 2023-02-14 4:23 pm Sale |
2022-12-31 | 13G | Vanda Pharmaceuticals Inc. VNDA |
Palo Alto Investors LP | 1,087,064 1.420% |
-1,747,180 (-61.65%) |
Filing History |
| 2023-02-14 4:22 pm Purchase |
2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Palo Alto Investors LP | 5,283,609 6.420% |
914,243 (+20.92%) |
Filing History |
| 2023-02-14 4:21 pm Purchase |
2022-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
Palo Alto Investors LP | 377,045 5.000% |
12,348 (+3.39%) |
Filing History |
| 2023-02-14 4:19 pm Sale |
2022-12-31 | 13G | Insmed Incorporated INSM |
Palo Alto Investors LP | 5,871,291 4.330% |
-154,415 (-2.56%) |
Filing History |
| 2023-02-14 4:18 pm Sale |
2022-12-31 | 13G | Epizyme, Inc. EPZM |
Palo Alto Investors LP | 0 0.000% |
-5,485,213 (Position Closed) |
Filing History |
| 2023-02-14 4:17 pm Purchase |
2022-12-31 | 13G | eHealth, Inc. EHTH |
Palo Alto Investors LP | 2,484,479 9.060% |
868,909 (+53.78%) |
Filing History |
| 2023-02-14 4:12 pm Unchanged |
2022-12-31 | 13G | Alimera Sciences, Inc. ALIM |
Palo Alto Investors LP | 802,423 11.450% |
0 (Unchanged) |
Filing History |
| 2022-02-14 5:11 pm Sale |
2021-12-31 | 13G | Epizyme, Inc. EPZM |
Palo Alto Investors LP | 5,485,213 5.280% |
-1,253,700 (-18.60%) |
Filing History |
| 2022-02-14 5:09 pm Purchase |
2021-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
Palo Alto Investors LP | 364,697 7.240% |
13,520 (+3.85%) |
Filing History |
| 2022-02-14 5:08 pm Sale |
2021-12-31 | 13G | Vanda Pharmaceuticals Inc. VNDA |
Palo Alto Investors LP | 2,834,244 5.090% |
-1,396,304 (-33.01%) |
Filing History |
| 2022-02-14 5:07 pm Purchase |
2021-12-31 | 13G | Alimera Sciences, Inc. ALIM |
Palo Alto Investors LP | 802,423 11.570% |
802,423 (New Position) |
Filing History |
| 2022-02-14 5:04 pm Purchase |
2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Palo Alto Investors LP | 4,369,366 6.090% |
4,369,366 (New Position) |
Filing History |
| 2022-02-14 5:03 pm Sale |
2021-12-31 | 13G | STAAR Surgical Company STAA |
Palo Alto Investors LP | 1,140,511 2.400% |
-1,708,837 (-59.97%) |
Filing History |
| 2022-02-14 5:01 pm Sale |
2021-12-31 | 13G | Insmed Incorporated INSM |
Palo Alto Investors LP | 6,025,706 5.090% |
-80,274 (-1.31%) |
Filing History |
| 2022-02-14 4:59 pm Sale |
2021-12-31 | 13G | CLOVIS ONCOLOGY INC CLVSQ |
Palo Alto Investors LP | 3,997,826 3.080% |
-471,585 (-10.55%) |
Filing History |